Establishment Labs Holdings
Market Cap
US$273.6m
Last Updated
2020/04/05 00:59 UTC
Data Sources
Company Financials +
Executive Summary
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Mediocre balance sheet with limited growth.
Similar Companies
Share Price & News
How has Establishment Labs Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ESTA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-15.0%
ESTA
0.08%
US Medical Equipment
-2.0%
US Market
1 Year Return
-52.9%
ESTA
-7.1%
US Medical Equipment
-15.1%
US Market
Return vs Industry: ESTA underperformed the US Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: ESTA underperformed the US Market which returned -15.1% over the past year.
Shareholder returns
| ESTA | Industry | Market | |
|---|---|---|---|
| 7 Day | -15.0% | 0.08% | -2.0% |
| 30 Day | -38.5% | -13.7% | -19.7% |
| 90 Day | -58.7% | -18.1% | -23.2% |
| 1 Year | -52.9%-52.9% | -6.3%-7.1% | -13.4%-15.1% |
| 3 Year | n/a | 42.4%38.5% | 10.9%3.7% |
| 5 Year | n/a | 71.1%53.4% | 28.4%14.4% |
Price Volatility Vs. Market
How volatile is Establishment Labs Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Establishment Labs Holdings Inc. Just Reported Earnings, And Analysts Cut Their Target Price1 month ago | Simply Wall St
What Type Of Shareholder Owns Establishment Labs Holdings Inc.'s (NASDAQ:ESTA)?2 months ago | Simply Wall St
Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?Valuation
Is Establishment Labs Holdings undervalued compared to its fair value and its price relative to the market?
6.11x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ESTA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ESTA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ESTA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: ESTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESTA is overvalued based on its PB Ratio (6.1x) compared to the US Medical Equipment industry average (2.9x).
Next Steps
Future Growth
How is Establishment Labs Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
28.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ESTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ESTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ESTA's revenue (25.5% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: ESTA's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESTA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Establishment Labs Holdings performed over the past 5 years?
-80.8%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ESTA is currently unprofitable.
Growing Profit Margin: ESTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ESTA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ESTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESTA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: ESTA has a negative Return on Equity (-96.3%), as it is currently unprofitable.
Next Steps
Financial Health
How is Establishment Labs Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ESTA's short term assets ($95.8M) exceed its short term liabilities ($23.2M).
Long Term Liabilities: ESTA's short term assets ($95.8M) exceed its long term liabilities ($53.7M).
Debt to Equity History and Analysis
Debt Level: ESTA's debt to equity ratio (121.5%) is considered high.
Reducing Debt: Insufficient data to determine if ESTA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: ESTA has a high level of physical assets or inventory.
Debt Coverage by Assets: ESTA's debt is covered by short term assets (assets are 2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESTA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ESTA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -17.3% each year.
Next Steps
Dividend
What is Establishment Labs Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ESTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ESTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Juan Jose Chacon Quiros (47yo)
7.25s
Tenure
US$483,516
Compensation
Mr. Juan Jose Chacon Quiros Founded Establishment Labs, S.A. in 2004 and has been its Chief Executive Officer. Mr. Chacon Quiros has been Chief Executive Officer and Executive Director of Establishment Lab ...
CEO Compensation Analysis
Compensation vs Market: Juan Jose's total compensation ($USD483.52K) is below average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Juan Jose's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.25yrs | US$483.52k | 6.1% $16.7m | |
| Chief Financial Officer | 2.75yrs | US$374.21k | no data | |
| Vice President of Sales | no data | US$429.33k | 0.039% $106.2k | |
| Chief Operating Officer | 4.17yrs | US$234.23k | 0.011% $29.8k | |
| Chief Technology Officer | 2.17yrs | no data | 0.025% $67.0k | |
| General Counsel | 2yrs | no data | no data |
2.8yrs
Average Tenure
38yo
Average Age
Experienced Management: ESTA's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.25yrs | US$483.52k | 6.1% $16.7m | |
| Independent Director | 2.33yrs | US$21.41k | no data | |
| Independent Director | 4.17yrs | US$19.59k | no data | |
| Independent Director | 4.42yrs | US$24.60k | 0.18% $489.9k | |
| Director | 0.83yr | no data | no data | |
| Chairman of the Board | 2.33yrs | US$4.53m | 3.33% $9.1m | |
| Independent Director | 4.25yrs | US$19.36k | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
4.2yrs
Average Tenure
61yo
Average Age
Experienced Board: ESTA's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.
Top Shareholders
Company Information
Establishment Labs Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Establishment Labs Holdings Inc.
- Ticker: ESTA
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$273.615m
- Shares outstanding: 23.33m
- Website: https://www.establishmentlabs.com
Number of Employees
Location
- Establishment Labs Holdings Inc.
- Buildings B15 and 25
- Coyol Free Zone
- Alajuela
- Costa Rica
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ESTA | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Jul 2018 |
| 3 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jul 2018 |
Biography
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in 80 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/05 00:59 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.